What Adare Pharma Solutions does

Adare Pharma Solutions is a private, technology-driven Contract Development and Manufacturing Organization (CDMO) specializing in small molecule oral dosage forms. The company provides end-to-end integrated services spanning product development, analytical services, formulation development, tech transfer, commercial-scale manufacturing, and packaging for pharmaceutical clients globally. It operates seven facilities across the United States (Philadelphia, PA — two sites; Vandalia, OH; Aurora, IL; Lenexa, KS) and Italy (San Giuliano Milanese and Pessano con Bornago), with capabilities covering DEA Schedule II-V controlled substance handling, high-potency compounds, organic solvent processing, fluid bed technology, and both GMP and non-GMP production.

The company's offering is anchored by twelve proprietary drug delivery technology platforms, including AdvaTab® (oral disintegration), Diffucaps® (controlled release with SS-SD bioavailability enhancement), Diffutab® (sustained release), Microcaps® (taste masking via coated particles), Minitabs™ (mini tablets), Parvulet® (pediatric/geriatric dosing), Stratμm™ (injectable micro-encapsulation), Optimμm®, Unisun® (intratympanic delivery), Adaptdose™ (which can eliminate reformulation after Phase I), and Duragran™ (controlled release granules). These are complemented by specialized services such as 3D screen printing, precision particle fabrication, nitrosamine mitigation, abuse-deterrent testing, and small-scale non-GMP laboratory work. Adare has launched 65+ products sold by customers in 100+ countries over a 30+ year legacy.

Adare operates a B2B enterprise sales model with field-based business development representatives serving as primary points of contact for pharmaceutical clients. Revenue is generated through project-based contracts covering tech transfer fees, development milestones, and commercial manufacturing and packaging fees, with services priced individually based on scope and volume. The company, previously known as Adare Pharmaceuticals, divested its Adare Biome postbiotics subsidiary to dsm-firmenich in July 2023 and relocated its global headquarters from New Jersey to Philadelphia, Pennsylvania in September 2024 with a $2.9 million Pennsylvania state investment. Tom Sellig serves as CEO and is also a board member of Achieve Life Sciences.

Name

Adare Pharma Solutions

Legal name

Adare Pharma Solutions

Website

https://adarepharmasolutions.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Adare Pharma Solutions is a private, technology-driven CDMO specializing in oral dosage forms, providing end-to-end development, manufacturing, and packaging services from seven facilities in the US and Italy to pharmaceutical clients globally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical contract manufacturing
• Oral dosage development
• Drug delivery technology
• CDMO services
• Formulation development

Headquarters

HQ city

Lawrenceville

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Full-service CDMO providing integrated services from product development through commercial manufacturing and packaging for oral dosage forms. Revenue generated through project-based contracts, tech transfer fees, manufacturing fees, and packaging services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Adare Pharma Solutions is a global technology-driven Contract Development and Manufacturing Organization (CDMO) providing end-to-end integrated services for small molecule oral dosage forms. Services span product development, formulation, analytical, tech transfer, clinical trial materials, commercial-scale manufacturing, and packaging, leveraging proprietary drug delivery platforms (taste masking, modified release, solubility enhancement, patient-centric dosing). The company operates seven cGMP facilities across the US and Europe.

Product overview

Adare Pharma Solutions is a global technology-driven CDMO (Contract Development and Manufacturing Organization) providing end-to-end integrated services from product development through commercial manufacturing and packaging, specializing in small molecule oral dosage forms. The company's portfolio consists of proprietary drug delivery technology platforms (AdvaTab®, Diffucaps®, Diffutab®, Microcaps®, Minitabs™, Parvulet®, Stratμm™, Optimμm®, Unisun®, Adaptdose™, Duragran™) that provide taste masking, customized release profiles, solubility enhancement, and patient-centric dosing solutions. These technology platforms are complemented by specialized services including analytical services, formulation development, pediatric formulations, nitrosamine mitigation, high-potency handling, and 3D screen printing. Manufacturing services span clinical trial materials, tech transfer, commercial-scale manufacturing, and packaging. The company operates seven facilities across the US and Europe with over 65 products launched globally.

Differentiator

Problem solved

Functional benefit

Brands

• Orbis Biosciences: Technology platform for specialized drug delivery solutions
• AdvaTab
• Diffucaps
• Diffutab
• Microcaps
• Minitabs
• Optimμm
• Parvulet
• Stratμm
• Unisun
• Adaptdose
• Duragran

Products and services

• Product Development Services Comprehensive development services covering early stage development, R&D, formulation, analytical testing, and specialized services for pharmaceutical clients developing oral dosage forms.
• Formulation Development Formulation development expertise in taste masking, customized release, multiparticulate systems, and patient-centered state-changing dosage forms for pharmaceutical clients.
• Analytical Services Comprehensive analytical testing services and stability studies across multiple temperature ranges supporting product development through Clinical Phases I-III and commercial-scale production.
• Pediatric Formulations Specialized formulation development services focused on pediatric patient needs including age-appropriate dosing forms and patient-centric technologies.
• Clinical Trial Materials GMP and Non-GMP capabilities for clinical trial material production, including dose-packs and kit assemblies for distribution directly into the field.
• Tech Transfer Dedicated transfer team services facilitating smooth project transfer to bring products to market quickly, from pre-established projects or tech transfer into facilities.
• Commercial-Scale Manufacturing Commercial scale manufacturing with deep range of standard and specialized offerings, flexible capacity ensuring projects delivered on time and on budget across multiple US and European sites.
• Commercial Packaging Services Full range of high-speed filling solutions for commercial and clinical supplies at two FDA-registered packaging facilities including DEA Schedule II-V handling.
• AdvaTab® Technology Platform Proprietary oral disintegration technology platform that masks bitter drug taste and rapidly dissolves in the mouth without water, designed for patient adherence and pediatric/geriatric populations.
• Diffucaps® Technology Platform Proprietary controlled drug delivery technology platform optimizing release profiles, with SS-SD technologies enhancing bioavailability by preserving a drug's amorphous form.
• Diffutab® Technology Platform Proprietary customized drug release technology platform for targeted delivery of high-dosage and sustained release products for once-daily administration.
• Microcaps® Technology Platform Proprietary taste-masking technology platform providing precisely and uniformly coated individual drug particles for smooth, pleasant mouthfeel with no aftertaste.
• Minitabs™ Technology Platform Proprietary mini tablet system combining tablet formulation simplicity with multiparticulate dosage form flexibility, featuring high drug-loading capability for controlled release.
• Parvulet® Technology Platform Proprietary patient-centric oral dosing innovation ideal for pediatric and geriatric populations as well as patients with swallowing difficulties.
• Stratμm™ Technology Platform Proprietary micro-encapsulation technology platform for precision injectable delivery that titrates drug release kinetics to enable novel injectable drug delivery products.
• Unisun® Technology Platform Proprietary intratympanic delivery technology platform for small molecules, peptides, monoclonal antibodies, proteins, and macromolecules for treatment of otic disorders.
• Solubility Enhancement Platform Proprietary platform improving solubility within the gastrointestinal tract using activation systems that break down drug particles to their thermodynamically activated form, increasing solubility profiles.
• High Potency Handling Services Specialized high-potency compound handling capabilities for potent pharmaceutical compounds with global manufacturing capacity in both US and Europe.
• 3D Screen Printing Services Advanced 3D screen printing technology services for pharmaceutical manufacturing enabling novel drug delivery formats and formulations.
• Precision Particle Fabrication™ Services Proprietary technology services for precision particle manufacturing as part of specialized pharmaceutical development offering.
• Nitrosamine Mitigation Services Specialized services for nitrosamine risk assessment and mitigation in pharmaceutical formulations supporting regulatory compliance.
• Abuse-Deterrent Testing Services Testing services for abuse-deterrent pharmaceutical formulations (Category 1 testing) supporting development of tamper-resistant dosage forms.

Quantifiable outcome

• 65+ products launched globally with customers in 100+ countries
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature14 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Achieve Life SciencescoreStrategic or Co-development Partner · 24 March 2026Adare Pharma Solutions partnered with Achieve Life Sciences as the primary commercial manufacturing partner for cytisinicline, a smoking cessation treatment. The partnership was established after FDA issued a Complete Response Letter citing cGMP issues at Achieve's previous third-party manufacturing facility in France. Adare completed technology transfer at its Vandalia, Ohio facility with analytical method transfer and first engineering batch completed. The partnership aims to reduce international pharmaceutical import risks and costs while ensuring supply chain redundancy and US-based manufacturing capability for potential H1 2027 commercial launch.
• RS ItaliasupportingStrategic or Co-development Partner · 19 January 2026Strategic partnership for MRO (Maintenance, Repair, and Operations) procurement transformation. RS Italia implemented RS PurchasingManager™ e-procurement platform and RSScanStock® inventory management services. Results included up to 30% savings on selected items, 95% reduction in logistics costs, 90% reduction in accounts payable processing time, and consolidation of PPE suppliers from 15 to 1. The partnership transformed a fragmented system of 400+ suppliers into an efficient digital model.
• Laxxon MedicalsupportingTechnology or Integration · 18 September 2024Collaboration for 3D printing technology in pharmaceutical manufacturing. Laxxon Medical brings pioneering 3D printing technology for a new generation of pharmaceutical products, while Adare contributes its CDMO expertise and manufacturing capabilities for oral dosage forms.

Scale indicators10 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Cambrex: Cambrex is a small-molecule-focused CDMO offering API development, drug product manufacturing, and analytical services. It is a closely comparable peer to Adare given its small-molecule API and finished-dose CDMO positioning.
• Fareva: Fareva is a French-headquartered global CDMO with significant European manufacturing footprint in oral, injectable, and topical dosage forms. It competes with Adare in oral solid dose CDMO services, with overlapping European and global pharmaceutical customers.
• Alcami Corporation: Alcami is a US-headquartered CDMO offering drug product development, manufacturing, and analytical services for small molecules. It competes with Adare on oral solid dose CDMO and analytical/sterile fill-finish services.
• Catalent: Catalent is a leading global CDMO offering oral, injectable, and biologic drug delivery and manufacturing services. It directly competes with Adare in small-molecule oral solid dose formulation, softgel technologies, and tech transfer services to pharma companies.
• Aenova Group: Aenova is a European CDMO specializing in solid and semi-solid dosage forms, including tablets, capsules, and softgels. It is comparable to Adare in oral solid dose CDMO services with a similar customer base of mid-sized pharma companies.
• Recipharm: Recipharm is a European-headquartered CDMO offering formulation development, manufacturing, and packaging of oral solid dose and other dosage forms. It is comparable to Adare in CDMO services for oral solid dose, with overlapping customer segments in Europe.
• Siegfried Holding: Siegfried is a Swiss-listed CDMO providing API and drug product manufacturing services for the pharma industry. It competes directly with Adare in small-molecule oral solid dose CDMO services, with comparable global manufacturing footprint.
• PCI Pharma Services: PCI Pharma Services is a global CDMO offering drug development, manufacturing, and packaging services with strong capabilities in clinical trial materials and commercial packaging. It is comparable to Adare on clinical-to-commercial packaging and integrated CDMO services.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Thermo Fisher's pharma services division (formerly Patheon) is a top-tier global CDMO offering small-molecule API and drug product development and commercial manufacturing. It competes with Adare on oral solid dose, high-potency handling, and integrated development-to-commercial services.
• Lonza: Lonza is one of the world's largest CDMOs serving pharma and biotech across small molecules, biologics, and cell & gene therapy. It is comparable to Adare as a broad CDMO offering oral solid dose development and commercial manufacturing, with greater scale and modality breadth.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/adare-pharmaceuticals

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adare Pharma Solutions